title: Brazil: An emerging partner in drug R&D.
abstract: With the need for innovation in drug discovery and development and changes to patent laws that are enabling greater IP protection, many pharmaceutical companies are pursuing international cooperation agreements with foreign companies as part of a global development strategy to enhance product pipelines. Brazil, the largest pharmaceutical market in Latin America, has improved its infrastructure, scientific and technological capabilities and has created a sustainable strategy to promote drug discovery research activities. Positive economic growth, a stable political structure, expanding patient populations an increasing governmental, private and foreign investments are creating a new landscape for drug R&D in the country. As Brazilian-based pharmaceutical companies become further established, new opportunities for partnerships and collaborative alliances are becoming available for the drug discovery process, as well as for co-manufacturing and co-marketing efforts. This feature review provides an overview of the Brazilian pharmaceutical market and discusses current opportunities, emerging trends and challenges for this expanding market.
authors.affiliation: Hospital Alemão Oswaldo Cruz, Scientific Department, São Paulo, Brazil. sbmf@sbmf.org.br
authors.forename: Debora G
authors.initials: DG
authors.lastname: Rodrigues
mesh_terms: D001938:Brazil; D002986:Clinical Trials as Topic; D003132:Commerce / Q000458:organization & administration; D055808:Drug Discovery; D004345:Drug Industry / Q000458:organization & administration* / Q000639:trends; D006801:Humans; D007391:International Cooperation; D012106:Research / Q000458:organization & administration*